Review of depot aripiprazole for schizophrenia
Farha Bilal Motiwala, Kim Stasia Siscoe, Rif S El-Mallakh Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA Abstract: Improving outcomes in schizophrenia generally requires an improvement in medication...
Main Authors: | Motiwala FB, Siscoe KS, El-Mallakh RS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-11-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/review-of-depot-aripiprazole-for-schizophrenia-a14976 |
Similar Items
-
Síndrome neuroléptico maligno por aripiprazol depot
by: A. Contreras Chicote, et al.
Published: (2023-06-01) -
Aripiprazole in schizophrenia: consensus guidelines.
by: Travis, M, et al.
Published: (2005) -
Clinical experience with the new double aripiprazole depot regime in a psychiatric hospitalization unit
by: Á. Moleón Ruiz, et al.
Published: (2022-06-01) -
Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
by: Kidambi N, et al.
Published: (2023-05-01) -
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
by: Saki Hattori, et al.
Published: (2023-03-01)